IMDX today
$2.39-$0.08 (-3.24%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourBearish
15 minDescending Triangle
5 minAscending Triangle
Daily trend turns up above $3.76
Key levels
Resistance$2.75
Resistance$2.42
Support$1.95
Latest news & SEC filings
EarningsiMDx sets November 16, 2026 date for third quarter results
DealiMDx Amends Chronix Merger Deal, Swaps 10% Royalty for 10% Sale Payment
AnalystLucid Capital Markets starts Insight Molecular coverage with Buy rating and $8 price target
All IMDX news →About Insight Molecular Diagnostics
Insight Molecular Diagnostics is a diagnostics company that develops molecular tests for detecting the rejection of transplanted organs and for cancer care. Its GraftAssure line measures a biomarker in blood to assess graft health, sold as a lab test, a research kit, and a clinical kit still in development. It also runs testing work for biotechnology and research customers. Its clients include hospitals, transplant centers, laboratories, and researchers, and it has facilities in Tennessee and Germany.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Insight Molecular Diagnostics Inc. (IMDX)
What Is the Price Target for IMDX?
SEPT Low Target
$7.22
SEPT Mid Target
$8.50
SEPT High Target
$9.77
Analyst Consensus
$8.50
Is IMDX a Buy or Sell Right Now?
Thesis
- •Revenue growing 115.6% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMDX.
Start Free Trial →Is IMDX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$8.50
59
Moat Score
NARROW
3/9
Piotroski Score
-27.1
Altman Z-Score
What Is Smart Money Doing with IMDX?
Insider Signal
BUYING
13 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SILVERMAN LOU | director | Buy | 26,943 | - | Jun 11, 2026 |
| Last Andrew J. | director | Buy | 26,943 | - | Jun 11, 2026 |
| Arno Andrew | director | Buy | 32,331 | - | Jun 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IMDX Growth Story
Revenue YoY
115.6%
3yr Revenue CAGR
61.8%
EPS Growth YoY
64.59%
FCF Growth YoY
-19.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for IMDX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IMDX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:44:14 | $2.41 | 1,900 | $$5K | MIDPOINT |
| 18:40:05 | $2.48 | 3,200 | $$8K | MIDPOINT |
| 18:39:47 | $2.43 | 7,687 | $$19K | SELL |
| 18:24:43 | $2.48 | 11,914 | $$30K | SELL |
| 16:05:54 | $2.53 | 13,809 | $$35K | SELL |
5 dark pool trades shown · $$96K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Insight Molecular Diagnostics Inc. (IMDX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMDX — frequently asked questions
What is IMDX stock price today?
Insight Molecular Diagnostics Inc. (IMDX) is at $2.39, down 3.24% (-$0.08) at the Nov 11, 2026 close.
Why is IMDX stock moving today?
Latest IMDX news — Nov 5, 2026: iMDx sets November 16, 2026 date for third quarter results · Sep 21, 2026: iMDx Amends Chronix Merger Deal, Swaps 10% Royalty for 10% Sale Payment
What is the IMDX price target?
The average analyst price target for IMDX is $8.50, ranging from $8 to $9, based on 2 analysts. Latest: LUCID CAPITAL MARKETS initiates on Aug 24, 2026.
What do analysts rate IMDX?
Analyst ratings for IMDX: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did IMDX beat earnings?
IMDX last reported on Aug 10, 2026: EPS -$0.31 vs -$0.25 expected — a miss of 22.0%.
Does IMDX pay a dividend?
IMDX does not currently pay a dividend.
What are IMDX support and resistance levels?
Support: $1.95. Resistance: $2.42, $2.75, $3.27.
What are insiders doing with IMDX?
Insider activity: BUYING, 13 buys and 0 sells in the last 90 days.
What is the latest news on IMDX?
Nov 5, 2026: iMDx sets November 16, 2026 date for third quarter results · Sep 21, 2026: iMDx Amends Chronix Merger Deal, Swaps 10% Royalty for 10% Sale Payment · Aug 24, 2026: Lucid Capital Markets starts Insight Molecular coverage with Buy rating and $8 price target